MPLT Executive Sells 1% of Direct Shares Ahead of 2026 Trial Data
An executive of MapLight Therapeutics (MPLT) sold 3,316 shares, representing 1% of their direct holdings, for approximately $88,000. The transaction occurred on April 15, 2026, and did not involve indirect or derivative shares. The sale has raised questions about its significance in relation to the company's upcoming 2026 trial data.
Topics: executive transactions MapLight Therapeutics SEC filings stock sales